Chronic lymphocytic leukemia patients with heterogeneously or fully methylated LPL promotor display longer time to treatment.

MLA

Daugaard, Iben, et al. “Chronic Lymphocytic Leukemia Patients with Heterogeneously or Fully Methylated LPL Promotor Display Longer Time to Treatment.” Epigenomics, vol. 10, no. 9, Sept. 2018, pp. 1155–66. EBSCOhost, https://doi.org/10.2217/epi-2018-0020.

APA

Daugaard, I., Hussmann, D., Kristensen, L., Kristensen, T., Kjeldsen, T. E., Nyvold, C. G., Larsen, T. S., Møller, M. B., Hansen, L. L., & Wojdacz, T. K. (2018). Chronic lymphocytic leukemia patients with heterogeneously or fully methylated LPL promotor display longer time to treatment. Epigenomics, 10(9), 1155–1166. https://doi.org/10.2217/epi-2018-0020

Chicago

Daugaard, Iben, Dianna Hussmann, Louise Kristensen, Thomas Kristensen, Tina E Kjeldsen, Charlotte G Nyvold, Thomas S Larsen, Michael B Møller, Lise Lotte Hansen, and Tomasz K Wojdacz. 2018. “Chronic Lymphocytic Leukemia Patients with Heterogeneously or Fully Methylated LPL Promotor Display Longer Time to Treatment.” Epigenomics 10 (9): 1155–66. doi:10.2217/epi-2018-0020.